Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as a nasal spray for nasal use. It treats acute migraine attacks in adults and provides rapid relief of headache pain and associated symptoms.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran is a Triptan indicated for the acute management of migraine and related headache disorders.

Migraine (with or without aura): provides rapid relief of headache pain, nausea, photophobia and phonophobia when administered at the onset of an attack. Cluster headache (episodic): can abort an individual cluster attack when taken early in the episode.

Common Side Effects: - Nasal irritation or burning sensation - Unpleasant taste or metallic sensation - Dizziness or light‑headedness - Mild nausea or abdominal discomfort - Throat irritation or dryness - Somnolence or fatigue

Serious or Rare Side Effects: - Coronary artery spasm or myocardial infarction - Stroke or transient ischemic attack - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with serotonergic agents - Anaphylactic or severe allergic reactions - Pulmonary edema or severe respiratory distress

Imigran should be used with caution in patients with cardiovascular or cerebrovascular disease.

Contraindicated in: Patients with known coronary artery disease, uncontrolled hypertension, or a history of stroke. Avoid use in: Individuals with hemiplegic or basilar migraine. Caution when combined with: Monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs. Pregnancy and lactation: Safety not established; prescribe only if benefits outweigh potential risks. Store at room temperature: keep in the original packaging, protect from moisture and direct heat.

Major Interactions (Avoid): - MAO inhibitors (within 14 days): risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstriction may precipitate cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers or antihypertensives: may enhance hypotensive effects. - Oral contraceptives: may slightly increase migraine frequency; monitor response. - CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma levels; adjust therapy if needed.